Individuals aected with neuro®bromatosis 1 (NF1) harbor increased numbers of GFAP-immunoreactive cerebral astrocytes and develop astrocytomas that can lead to blindness and death. Mice heterozygous for a targeted Nf1 mutation (Nf1+/7) were employed as a model for the human disease to evaluate the hypothesis that reduced NF1 protein (neuro®bromin) expression may confer a growth advantage for astrocytes, such that inactivation of only one NF1 allele is sucient for abnormal astrocyte proliferation. Here, we report that Nf1+/7 mice have increased numbers of cerebral astrocytes and increased astrocyte proliferation compared to wild-type littermates. Intriguingly, primary Nf1+/7 astrocyte cultures failed to demonstrate a cell-autonomous growth advantage unless they were cocultured with C17 neuronal cells. This C17 neuronal cellinduced Nf1+/7 increase in proliferation was blocked by MEK inhibition (PD98059), suggesting a p21-rasdependent eect. Furthermore, mice heterozygous for a targeted mutation in another GAP molecule, p120-GAP, demonstrated no increases in cerebral astrocyte number. These ®ndings suggest that reduced NF1 expression results in a cell context-dependent increase in astrocyte proliferation that may be sucient for the development of astrocytic growth abnormalities in patients with NF1.
Introduction
Neuro®bromatosis 1 is a common autosomal dominant disorder in which aected individuals develop both benign and malignant tumors at an increased frequency (Bader, 1986; Riccardi, 1992) . One of the most common tumors in NF1 is the glioma or astrocytoma (Listernick et al., 1997; Gutmann et al., 1997) . Although these tumors typically occur in the optic pathway and sometimes lead to visual compromise and neurological dysfunction, they are also found in the brainstem and other regions of the brain (Molloy et al., 1995; Pollack et al., 1996) . Advances in our understanding of the molecular pathogenesis of the clinical features of NF1 have resulted from the identi®cation of the NF1 gene and the elucidation of its protein function. The NF1 tumor suppressor gene was identi®ed by positional cloning and found to encode a 220 ± 250 kiloDalton cytoplasmic protein termed neuro®bromin Viskochil et al., 1990; Wallace et al., 1990) . Neuro®bromin is expressed in many cell types and tissues, including neurons, astrocytes, Schwann cells, oligodendrocytes, blood vessels, adrenal medulla, gonadal tissues, and white blood cells (DeClue et al., 1991; Gutmann et al., 1991 Gutmann et al., , 1995 Daston et al., 1992; Golubic et al., 1992; Datson and Ratner, 1993; Huynh et al., 1992) . Sequence analysis demonstrated that a small central domain of neuro®bromin shares similarity with the catalytic domain of proteins involved in p21-ras regulation (Ballester et al., 1990; Martin et al., 1990; Xu et al., 1990a,b) . These GTPase-activating proteins (GAPs) function to accelerate the inactivation of the p21-ras protein from its active GTP-bound to its inactive GDP-bound form (Bollag and McCormick, 1991) . Since p21-ras can transform ®broblasts and increase cell proliferation in vitro, neuro®bromin has been hypothesized to negatively regulate cell growth by inactivating p21-ras. In support of this mechanism, several studies have shown that neuro®bromin suppresses cell growth by inhibiting p21-ras activity in some cell types. These results are consistent with the notion that the tumor suppressor function of neurofibromin is related to its ability to operate as a GAP molecule (Basu et al., 1992; DeClue et al., 1992; Bollag et al., 1996; Largaespada et al., 1996) . However, little is known about the function of neuro®bromin in astrocytes relevant to the development of astrocytomas in individuals aected with NF1.
Previous work from our laboratory and others has demonstrated that increased p21-ras activity is a common feature of sporadic malignant astrocytomas Guha et al., 1997) . Inhibition of p21-ras activity in astrocytoma tumor cells results in reduced cell proliferation both in vitro and in vivo (Guha et al., 1997) . The increase in p21-ras activation in astrocytomas is the direct result of altered signaling through the epidermal growth factor receptor (EGF-R), such that more p21-ras is converted from the inactive GDP to the active GTP bound conformation. In these sporadic astrocytomas, there is no loss of neuro®bromin expression , arguing that only one alteration in the p21-ras signaling pathway (either EGFR activation or absent neuro®bromin) is necessary for astrocytoma development or progression. Since individuals aected with NF1 develop astrocytomas and the NF1 gene product functions as a p21-ras regulator, we tested the hypothesis that reduced NF1 expression would be sucient to confer a growth advantage on astrocytes. In this report, we demonstrate that mice heterozygous for a targeted Nf1 mutation have increased numbers of cerebral astrocytes and increased astrocyte proliferation in vivo. We further show that this increase in astrocyte proliferation is dependent on neuronal-like cell contact in vitro. Lastly, mice heterozygous for a targeted mutation in another GAP molecule, p120-GAP, fail to demonstrate similar increases in cerebral astrocytes. These results suggest that haploinsuciency for Nf1 expression confers a context-dependent growth advantage for astrocytes that may account for the astrocyte growth abnormalities seen in NF1.
Results
Astrocyte NF1 expression correlates with growth arrest in vitro Previous work from our laboratory has demonstrated that NF1 expression increases in astrocytes in response to cerebral ischemia, pro-in¯ammatory cytokines, cAMP activation, and tumor formation (Hewett et al., 1995; Giordano et al., 1996) . These results suggest that neuro®bromin might function during the astrogliotic response in the brain. In response to cerebral ischemia, the time course of increased neuro®bromin expression occurred after 4 ± 7 days, consistent with periods of astrocyte growth arrest and not proliferation (Janeczko, 1988) . To determine whether NF1 expression was associated with growth arrest in vitro, primary astrocyte cultures were established from 129sv wild type mice and maintained as a function of days in vitro. Parallel cultures were analysed for NF1 mRNA expression (RT ± PCR analysis; Figure 1a ), neurofibromin expression (Western blot analysis; Figure 1b) , and FACS analysis (Figure 1a ). The doubling time of primary astrocyte cultures was approximately 4 days as determined by BrdU pulse-chase FACS analysis (data not shown). We have previously shown that primary astrocytes reach con¯uence by 12 ± 14 days in vitro and undergo growth arrest presumably due to contact inhibition. FACS analysis of parallel cultures demonstrated that 70 ± 80% of the astrocytes were in G 0 /G 1 prior to day 14 in vitro compared to 94 ± 95% of the astrocytes in G 0 /G 1 after that time. NF1 RNA and protein expression increased dramatically by 10 days in vitro when 80% of the astrocytes are in G 0 /G 1 , just prior to the onset of astrocyte growth arrest. These ®ndings argue that the increase in NF1 expression is associated with the onset of growth arrest in astrocytes and is consistent with the notion that neuro®bromin may function as a growth regulator for astrocytes.
Nf1+/7 mice demonstrate increased numbers of astrocytes in vivo
In one post-mortem study, increased numbers of astrocytes were detected in the brains of several patients with NF1 (Nordlund et al., 1995) . It is presumed, although not proven, that these astrocytes have one normal and one mutated NF1 allele. These results suggest that reduced, but not absent, NF1 expression might result in abnormal astrocyte proliferation. In keeping with the Knudson two hit hypothesis, loss of both copies of NF1 by mutation would likely result in the development of an astrocytoma (Knudson, 1971) . We reasoned that reduced NF1 gene expression in astrocytes might lead to mild increases in astrocyte number without overt tumor formation.
Homozygous disruption of Nf1 in mice leads to embryonic lethality (*E12.5) whereas mice heterozygous for a targeted Nf1 mutation develop pheochromocytomas and leukemias, but not the typical tumors (neuro®bromas, astrocytomas) seen in individuals with NF1 (Brannan et al., 1994; Jacks et al., 1994) . To determine whether a haploinsucient eect is observed in mice with reduced neuro®bromin expression, the number of glial ®brillary acidic protein (GFAP)-immunoreactive astrocytes from Nf1+/7 mouse brains were counted in several well-de®ned areas of the brain (corpus callosum, dentate gyrus, cerebellum and hippocampus CA1 region). Increased numbers of Figure 1 Expression of neuro®bromin during astrocyte growth arrest in vitro. (a) Primary astrocyte cultures were established from sv129 mice and maintained for 6 ± 18 days in vitro (DIV) prior to harvest for FACS analysis using the Becton Dickinson FACScan or RNA analysis using semi-quantitative RT ± PCR with primers that amplify the GAP-related domain of NF1 or cyclophilin (internal control for RNA quantity and quality). The arrows denote NF1 mRNA containing (upper band) or lacking (lower band) exon 23a. The per cent of astrocytes in G 0 /G 1 as determined by FACS analysis are shown as a function of days in vitro. (b) Primary astrocyte cultures maintained for 4 ± 14 days in vitro were harvested and equal amounts of total protein were separated by 8% SDS ± PAGE for immunoblotting with WA15a (neuro®bromin) and tubulin (internal loading control) antibodies. The arrow denotes neuro®bromin (220 kDa protein). Increased NF1 RNA and protein expression was detected by DIV 10 prior to growth arrest as determined by FACS analysis (80 ± 94% of the cells in G 0 /G 1 ) GFAP-immunoreactive astrocytes were observed in Nf1+/7 brains compared to wild type littermates (right hippocampus; Figure 2a ). Approximately 40% more astrocytes were detected in Nf1+/7 brains, regardless of strain or sex (Figure 3a ) as well as age or brain region (data not shown). This increase in astrocyte GFAP immunoreactivity was also con®rmed by Western blotting from homogenized forebrains from pools of at least three mice from each genotype or strain (Figure 2b ). In contrast, no increases in mac-1-immunoreactive microglia (Figure 3b ) or APC immunoreactive oligodendrocytes ( Figure 3c ) were observed, arguing that only type 1 astrocytes and not other glial cell lineages were aected by reduced Nf1 expression.
Nf1+/7 astrocytes lack a cell-autonomous growth advantage in vitro To better de®ne the growth advantage of Nf1+/7 astrocytes, primary astrocyte cultures were established from individual pups in 21 litters. Whereas increased GFAP expression was detected in forebrain homogenates, no dierences in GFAP expression were detected in cultured astrocytes from Nf1+/7 and Nf1+/+ wild type mice ( Figure 4a) . Surprisingly, these Nf1+/7 astrocyte cultures did not demonstrate increased cell proliferation as detected by BrdU incorporation (not shown), direct cell counts (not shown), and thymidine incorporation ( Figure 4b ). Direct cell counting using Trypan Blue exclusion failed to demonstrate any changes in astrocyte cell viability in Nf1+/+ compared to Nf1+/7 cultures (data not shown). Furthermore, no dierences in proliferation were detected between Nf1+/+ and Nf1+/7 astrocytes under serum starvation conditions, with and without epidermal growth factor stimulation, or in response to serum challenge (not shown). These ®ndings suggested that the increase in astrocyte number observed in the Nf1+/7 brains did not result from a cell-autonomous defect in astrocyte growth regulation.
Experiments on leukemic cells from Nf1 7/7 mice have shown that resting, unstimulated cells do not demonstrate increased proliferation and p21-ras activity. Only after granulocyte-macrophage colony stimulating factor (GM ± CSF) treatment are the increases in cell proliferation and p21-ras pathway activation manifested (Bollag et al., 1996; Largaespada et al., 1996) . Similar experiments on Nf1+/7 astrocytes failed to demonstrate dierences between wild-type and Nf1+/7 astrocytes with regard to p21-ras pathway activation after EGF treatment. In these experiments, Nf1+/+ and Nf1+/7 astrocyte cultures were serum starved overnight prior to EGF stimulation. Ras pathway activation was measured using phospho-speci®c MAPK antibodies ( Figure 4c ) and in vitro MAPK assays (not shown). Collectively, these data suggest that no signi®cant cell-autonomous dierences in astrocyte proliferation and MAPK pathway activation result from NF1 haploin sufficiency. Figure 2 Nf1+/7 mice demonstrate increased numbers of GFAP-immunoreactive astrocytes. (a) Comparable representative 40 mm sections from Nf1+/7 and wild type littermate sv129 mice were immunostained with GFAP antibodies and developed with Vectastain SG to demonstrate increased numbers of astrocytes in the heterozygous Nf1 mutant mice. These sections are taken from the hippocampus at 406magni®cation. The bar denotes 50 microns. Arrows point to GFAP-immunoreactive astrocytes. (b) Western blot analysis of forebrain homogenates pooled from at least three C57B1/6 (Nf1+/+, lane 1 and Nf1+/7, lane 2) and sv129 (Nf1+/+, lane 3 and Nf1+/7, lane 4) mice. Equal amounts of total protein were separated by SDS ± PAGE. Increased GFAP is detected in the Nf1 heterozygote mutant mice compared to the littermate controls. Tubulin is included as a control for equal protein loading Increased proliferation of Nf1+/7 astrocytes in response to neuronal contact
The lack of increased astrocyte proliferation in vitro raised the possibility that the observed increases in GFAP-immunoreactive astrocytes in the brain re¯ected reactive astrogliosis and not increased proliferation (Rizvi et al., 1999) . Alternatively, it is possible that reduced Nf1 expression does not confer a cell autonomous growth advantage, but rather an abnormal response to other stimuli. We therefore tested the hypothesis that the increase in astrocyte number in Nf1+/7 brains re¯ected an increase in cell proliferation. First, litters of Nf1 pups (5 ± 8 weeks of age) were injected with 5 mg/g BrdU 48 h prior to perfusion and double-label immunohistochemistry with GFAP and BrdU antibodies. The percentage of astrocytes (GFAPimmunoreactive cells) with nuclear BrdU immunoreactivity in the dentate gyrus and hippocampus CA1 region was determined. We detected an increase in the percentage of proliferating astrocytes in Nf1+/7 compared to wild type Nf1+/+ mice (Figure 5a ). On average, approximately twofold increased astrocyte proliferation was observed in the Nf1+/7 brains.
We reasoned that this increase in astrocyte proliferation might re¯ect an abnormal response on the part of the Nf1+/7 astrocytes to neuronal contact or stimuli.
To develop an in vitro correlate for this neuronal context-dependent eect on astrocyte proliferation, we established primary astrocyte cultures from wild type and Nf1+/7 littermates grown in the presence or absence of lightly ®xed and extensively washed C17 neuronal cells. This cell line was chosen based on previous experiments demonstrating that they display some properties of neurons and can interact with astrocytes (Ryder et al., 1990; Weinstein et al., 1990) . No thymidine incorporation was detected with the ®xed C17 cells alone in the absence of astrocytes (not shown). Astrocytes from Nf1+/7, but not wild type Nf1+/+, mice demonstrated a statistically signi®cant increase in thymidine incorporation in response to C17 cell coculture (Figure 5b ). This increase in proliferation ranged between 1.7-and 1.8-fold.
We next determined whether this increase in astrocyte proliferation in response to neuronal-like cell contact resulted in changes in p21-ras pathway activation.
Initial experiments failed to demonstrate reproducible changes in MEK activity between Nf1+/7 astrocyte cultures cultured in the presence or absence of C17 neuronal-like cells (data not shown). Similarly, no signi®cant changes in p38-MAPK or Akt activation were observed (data not shown). Although no changes in p21-ras pathway activity were detected, we reasoned that reduced Nf1 expression in the context of C17 co-B Figure 3 Nf1+/7 mice demonstrate a speci®c increase in GFAP-immunoreactive astrocytes. (a) Quantitation of the representative results shown in Figure 2a was performed for at least six mice from each genotype, sex, and strain (C57B1/6 and sv129). These counts derive from right hippocampal CA1 sections. Asterisks denote statistical signi®cance (P50.001) by the Student's t-test. No changes in the number of mac-1-immunoreactive microglia (b) or APC-immunoreactive oligodendrocytes (c) were observed in sv129 hippocampal CA1 sections culture could result in increased cell proliferation in a p21-ras-dependent fashion, but these changes fell below the threshold of detectability in our assays. To determine whether this context-dependent increase in Nf1+/7 astrocyte proliferation could be abrogated by p21-ras pathway inhibition, cultures were treated with 50 mM PD98059 (MEK inhibitor). As shown in Figure  5c , PD98059 treatment of Nf1+/7 astrocytes (cultures #2 and #4) co-cultured with C17 cells reduced the proliferation to levels observed in the astrocytes cultured without C17 cells. In contrast, no eect of PD98059 treatment on proliferation was observed on the wild type astrocytes (cultures #1 and #3). These results suggest that the context-dependent increase in astrocyte proliferation is dependent on p21-ras activation.
It is unlikely that the increase in GFAP expression detected in Nf1+/7 mouse brains re¯ected astrogliosis. Although increased GFAP expression was detected in the Nf1+/7 brains compared with the wild type littermate brains (Figure 2b ), no increase in GFAP expression was detected in cultured Nf1+/7 astrocytes compared to wild type astrocytes in vitro (Figure 4a) . Furthermore, no signi®cant changes in GFAP expression were noted in Nf1+/7 astrocytes when co-cultured with C17 cells either (Figure 6 ).
Increased astrocyte proliferation is a neuro®bromin-speci®c eect
To determine whether any reduction of rasGAP activity is sucient to result in increased astrocyte Figure 4 Primary Nf1 astrocytes fail to demonstrate a cell-autonomous defect in growth regulation. (a) Primary astrocyte cultures from sv129 Nf1+/7 and wild type mice expressed equal amounts of GFAP by Western blotting. Equal amounts of total protein were separated by SDS ± PAGE prior to immunoblotting with GFAP and tubulin antibodies. (b) Primary astrocyte cultures from sv129 Nf1+/7 and Nf1+/+ littermates grown in complete media and analysed by thymidine incorporation failed to demonstrate reproducible dierences in proliferation. Error bars represent standard deviations for six duplicate wells. (c) Primary astrocytes from two representative sv129 Nf1+/7 and Nf1+/+ cultures were serum starved overnight prior to stimulation with EGF (100 ng/ml). Cultures were harvested after 10, 20, 30 and 60 min and analysed using phospho-speci®c p42/44-MAPK and p38-MAPK antibodies. Tubulin is included as a control for equal protein loading. No dierences in the magnitude of the increase in MAPK activation following EGF stimulation were observed between Nf1+/+ and Nf1+/7 astrocyte cultures after quantitation by scanning densitometry proliferation, we examined mice heterozygous for a mutation in the another rasGAP molecule, p120-GAP. Mice homozygous for a targeted mutation in the Gap gene are embryonic lethal while heterozygotes fail to develop astrocytic tumors (Henkemeyer et al., 1995) . We quantitated the number of GFAP-immunoreactive astrocytes in representative regions of the brain and detected no reproducible dierences between wild type and Gap+/7 mice (right CA1 region; Figure 5d ). These ®ndings suggest that a general reduction in rasGAP activity is not sucient to confer a growth advantage for astrocytes and argue that the increase in astrocyte proliferation observed in the Nf1+/7 mice is a neuro®bromin-speci®c eect.
Discussion
Since individuals aected with NF1 commonly develop astrocytomas, the NF1 tumor suppressor gene is thought to function as a negative growth regulator for astrocytes. Neuro®bromin is expressed at low levels in resting mature astrocytes both in vitro and in vivo Figure 5 Nf1+/7 astrocytes when in contact with neurons or neuronal-like cells demonstrate increased cell proliferation in vitro and in vivo. (a) Nf1+/7 and wild type Nf1+/+ sv129 littermates (5 ± 6 weeks of age) were injected with BrdU and the percentage of BrdUimmunoreactive astrocytes determined 48 h later by double-labeled immunohistochemistry. The percentage of proliferating astrocytes was approximately twofold greater in the Nf1+/7 mice compared to their wild type littermates. Asterisks denote statistical signi®cance (P50.001) using the Student's t-test. (b) Ten thousand primary astrocytes from sv129 mice were cultured in the presence (+C17) or absence of 10 000 lightly ®xed C17 neuronal cells per well for 72 h prior to thymidine incorporation. Increased proliferation (1.7 ± 1.8-fold) was observed in the Nf1+/7 cultures, but not in the wild type cultures. Asterisks denote statistical signi®cance (P50.001) using the Student's t-test. (c) Ten thousand primary astrocytes were cultured in the presence (+C17) or absence of 10 000 lightly ®xed C17 neuronal cells per well for a total of 72 h prior to the addition of the PD98059 MEK inhibitor for 24 h during the period of tritiated thymidine incorporation. Cultures 1 and 3 represent astrocytes from Nf1+/+ wild type mice whereas cultures 2 and 4 are astrocytes from Nf1+/7 mice. Increased astrocyte proliferation was observed in the Nf1+/7 cultures in the presence of ®xed C17 cells. This increase in proliferation was inhibited by the addition of 50 mM PD98059. The mean and standard deviation are shown for each condition. The astrocytes shown in this experiment represent fresh cultures and are not the same cultures shown in (b). (d) The number of GFAP-immunoreactive astrocytes in the right hippocampus CA1 region from Gap+/7 and wild type Gap+/+ littermates (5 ± 6 weeks of age) was determined. No dierences in the number of astrocytes were detected in Gap+/7 compared to wild type littermate mice. Error bars denote standard deviations for at least six serial sections from each mouse Figure 6 C17 cell co-culture does not result in increased GFAP expression. Ten thousand primary astrocytes were cultured in the presence (+C17) or absence of 10 000 lightly ®xed C17 neuronal cells per¯ask for 96 h prior to harvest in MAPK lysis buer on ice. Equal amounts of total protein were separated by 10% SDS ± PAGE and analysed with GFAP antibodies by Western blot. The Nf1 genotypes are denoted on the top (+/+ or+/7) while the presence (+) or absence (7) of C17 cells are denoted along the bottom of the ®gure. No signi®cant changes in the expression of GFAP or tubulin (not shown) were noted in these cultures (Nordlund et al., 1993; Hewett et al., 1995) . During astrocyte activation in vitro, in response to elevations in cAMP levels or in response to pro-in¯ammatory cytokines, there is a dramatic upregulation of NF1 mRNA and protein expression (Hewett et al., 1995) . Similarly in vivo, increased NF1 expression is observed in activated astrocytes in response to cerebral ischemia or tumor xenograft implantation (Gutmann, unpublished observations) . The time course of increased neuro®bromin expression correlates with periods of astrocyte growth arrest and not proliferation, suggesting that upregulation of NF1 expression is associated with negative growth regulation. In this study, we demonstrate that increased neuro®bromin expression precedes astrocyte growth arrest in vitro. These results provide indirect evidence that neuro®bromin functions as a negative growth regulator for astrocytes.
To provide more direct proof for a growth regulatory function of neuro®bromin in astrocytes, we employed an animal model in which mice were heterozygous for a targeted mutation in the Nf1 gene. These mice are genetically similar to individuals aected with NF1 in that they harbor one wild type and one mutant NF1 allele in every cell of the body. Previous autopsy studies on NF1 patient brains demonstrated increased GFAP-immunoreactive astrocytes (Nordlund et al., 1995) . In this report, we demonstrate that Nf1+/7 mice demonstrate increased numbers of GFAP-immunoreactive astrocytes in the brain, similar to that described for individuals aected with NF1. Recently, Ratner and colleagues have reported similar increases in GFAP-immunoreactivity in brains from mice heterozygous for a targeted Nf1 mutation, con®rming the observations reported herein (Rizvi et al., 1999) . We further demonstrate that this increase in GFAP-immunoreactive astrocytes re¯ects increased astrocyte proliferation both in vitro and in vivo. We show that the increase in Nf1+/7 astrocyte proliferation is not a cell-autonomous property of these astrocytes but rather appears to be a cell context-and p21-ras-dependent event that requires neuronal-like cell contact. Lastly, we demonstrate that Gap+/7 mice fail to demonstrate any changes in astrocyte proliferation. These results argue that this astrocyte proliferative eect is neuro®bromin-speci®c and is not re¯ective of a general rasGAP eect on astrocytes.
Previous studies on the eects of neurons on astrocyte proliferation have demonstrated that neurons and neuronal membranes can exert an inhibitory eect on astrocyte proliferation (Sobue and Pleasure, 1984; Eccleston et al., 1989) . In these reports, rat central nervous system axolemmal fragments induced phenotypic alterations in cultured astrocytes concomitant with greater than a 50% reduction in tritiated thymidine incorporation. Similarly, co-culture of guinea-pig enteric neurons with rat Schwann cells or astrocytes reduced Schwann cell and astrocyte proliferation in vitro. In contrast, guinea-pig dorsal root ganglia neurons or bovine axolemma fractions stimulated astrocyte tritiated thymidine incorporation, similar to what has been reported for Schwann cells (Eccleston et al., 1989) . The C17 retrovirally immortalized neuronal-like cell line has been shown to inhibit astrocyte and astrocytoma proliferation in a dosedependent manner (Weinstein et al., 1990) . However, using primary astrocytes, the ratio of ®xed C17 cells to astrocytes was critical: Only 17.4% inhibition was observed at a 1 : 1 ratio whereas 94% inhibition was observed when the C17 : astrocyte cell ratio was 10 : 1. In our experiments, we determined that the maximal C17 cell proliferative eect on the Nf1+/7 astrocytes was observed at a 1 : 1 ratio with no growthstimulatory eect observed at a 10 : 1 ratio. Furthermore, the lightly ®xed C17 cells were loosely adherent to the astrocytes and, in this fashion, may have behaved more like axonal membranes than living neurons. We are presently exploring the nature of this inhibition using C17 membrane fractions to better characterize the Nf1+/7 astrocyte growth promoting eect.
The data presented in this report suggest that reduced neuro®bromin expression is sucient to confer a context-dependent growth advantage for astrocytes in the brain. This minor increase in astrocyte proliferation is not sucient for tumor formation, since no gliomas have been observed in Nf1+/7 mice (Jacks et al., 1994) . It may be enough, however, to account for the observation that astrocyterich white matter regions appear to be selectively increased in children with NF1 (Said et al., 1996; Greenwood et al., 1997) . Similarly, NF1 haploinsufficiency may also be sucient to result in the increase in astrocyte number observed in NF1 patient brains (Nordlund et al., 1995) .
One of the clinically puzzling features of NF1-associated optic pathway gliomas is the variable behavior of these tumors (Listernick et al., 1989; Habiby et al., 1995) . The majority of these optic pathway gliomas are clinically asymptomatic and do not enlarge to result in visual impairment or blindness. In this fashion, these tumors behave as benign growths. In contrast, some of the NF1-associated astrocytomas grow rapidly and lead to blindness or neurologic compromise as a result of tumor extension. The fact that gliomas do not form as a consequence of Nf1 haploinsuciency suggests that additional genetic changes are required.
One of these additional genetic events might involve loss of the one remaining wild type Nf1 allele, resulting in a complete absence of neuro®bromin expression in selected astrocytes in the brain. In agreement with the Knudson two hit hypothesis, loss of both functional Nf1 alleles might be associated with tumor formation. We would hypothesize that these tumors lacking neuro®bromin expression represent the`benign' clinically non-progressive tumors seen in as many as 10% of patients with NF1. To develop a clinically aggressive optic pathway glioma in NF1, mutations in other tumor suppressor genes (e.g. p53) might be required to facilitate malignant transformation. In support of this notion, cooperation between p53 inactivation and increased ras activity has been reported for Schwann cells, such that both events are required to confer increased Schwann cell proliferation (Ridley et al., 1989) .
Substantial experimental data exist for a rasGAP growth suppressor function of neuro®bromin in some cell types. However, it is not clear whether neurofibromin functions as a negative growth regulator for astrocytes by modulating p21-ras pathway activation.
In this report, we demonstrate that the increase in primary Nf1+/7 astrocyte proliferation in response to ®xed C17 cells is inhibited by blocking MEK activity. These results argue that the increase in proliferation is the result of increased p21-ras pathway activation as a consequence of decreased neuro®bromin GAP function. Studies are ongoing in our laboratory to more completely characterize this neuro®bromin eect on p21-ras pathway activity in astrocytes.
The development of sporadic astrocytomas involves a multi-step process of genetic and biochemical alterations. One of the most common alterations observed in high grade gliomas is increased activation of p21-ras Guha et al., 1997) . In the case of sporadic astrocytomas, this increase in p21-ras activity results from abnormal activation of the positive regulators of p21-ras, as a consequence of augmented EGF-R signaling (Guha et al., 1997) . Activation of the EGF-R results in recruitment of the shc adaptor protein and the hSOS guanosine nucleotide replacing factor (GNRF), culminating in activation of p21-ras by the exchange of GDP for GTP. Inhibition of EGF-R signaling or p21-ras activation in glioma cells results in decreased cell proliferation both in vitro and in vivo. In a similar fashion, it is possible that loss of neuro®bromin expression in NF1 astrocytomas could also result in increased p21-ras activation through absent neuro®bromin GAP function. In either case, increased GNRF or decreased neuro®bromin GAP activity might provide p21-rasdependent mitogenic signals for astrocytes relevant to the development of an astrocytoma.
With regard to p21-ras activation and cell proliferation, it is not known whether p21-ras activation is necessary or sucient for astrocyte proliferation or tumor formation. It is clear that inhibition of p21-rasinduced MAPK activation results in reduced astrocytoma growth, but these experiments have been performed on astrocytoma cell lines with multiple genetic alterations, including mutations at TP53. Experiments are presently underway to determine both in vitro and in vivo whether p21-ras activation in astrocytes results in increased cell proliferation, neoplastic transformation and astrocytoma tumor development. Further studies on the mechanism of neuro®bromin astrocyte growth regulation will likely provide pharmacologic targets for the treatment of these tumors.
Materials and methods

Primary astrocyte cultures
Nf1+/7 mice were generously provided by Dr Neal Copeland (National Cancer Institute) (Brannan et al., 1994) . Gap+/7 mice have been previously described (Henkemeyer et al., 1995) . Both are maintained as continuous colonies at Washington University. Heterozygotes and wild type mice were genotyped from tail DNA obtained at the time of weaning using published primer sets. Primary astrocyte cultures (497% pure astrocytes) were established from postnatal day 1 ± 3 newborn pups as previously described (Hewett et al., 1993; Rose et al., 1993) . Astrocyte purity was assessed using cell type-speci®c antibodies (GFAP for astrocytes, MAP2 for neurons, and GalC for oligodendrocytes). Brie¯y, cerebral cortices were dissected and enzymatically digested in 0.09% trypsin for 20 ± 30 min. Cultures were maintained in modi®ed Eagle's medium supplemented with 2 mM glutamine, 20 mM glucose, 10% fetal bovine serum, 10% horse serum, 1% pen-strep and 10 ng/ml epidermal growth factor. Thymidine incorporation was performed by pulsing astrocytes with 1 mCi tritiated thymidine (Amersham) per ml for 24 h in 24 well plates (six wells per culture or condition). Labeled cells were washed in PBS and solubilized in 200 ml of 0.2 M NaOH. Counts were then determined in a scintillation counter. The percentage of astrocytes in G 0 /G 1 was determined by FACS analysis on a Becton Dickinson FACScan as previously described (Norton et al., 1995) .
RNA and protein analysis
Western blotting was performed using WA15a (pan neuro®bromin; Gutmann et al., 1996) , tubulin (clone DM1-A; Sigma), GFAP (Zymed), and activation-speci®c phospho-MAPK and p38-MAPK (Promega) antibodies with HRPconjugated secondary antibodies (Sigma) and ECL development (Amersham). Primary antibodies were used according to the manufacturer's recommendations while WA15a was used at a 1 : 300 dilution (Basu et al., 1992; Norton et al., 1995a,b) . For experiments involving MAPK determinations, cultures were serum starved overnight prior to stimulation with serum containing 100 ng/ml EGF for 60 min and collected by direct harvest in MAPK lysis buer (20 mM Tris, pH 7.5; 10 mM EGTA, 40 mM beta-glycerophosphate; 1% NP40; 2.5 mM MgCl 2 ; 2 mM orthovanadate) on ice. In vitro MAPK assays were performed according to published protocols using a rabbit polyclonal ERK2 antibody (Santa Cruz Biotechnology), myelin basic protein (Sigma) and 1 mCi [a-32 P]ATP (Amersham) in the presence of DTT. Forebrain tissue was carefully dissected from freshly euthanized mice of at least 3 months of age and homogenized in RIPA buer containing protease inhibitors prior to separation by SDS ± PAGE. RNA was extracted for semi-quantitative RT ± PCR analysis using a previously reported NF1 primer set that ampli®es sequences within the GAP-related domain and a cyclophilin primer set to control for RNA quality and quantity (5'-ATGGTCAACCC-CACCGTGTT-3' and 5'-CGTTGTAAGTCACCACCCT-3') . RT ± PCR products were resolved by non-denaturing PAGE.
C17 neuronal cell co-culture C17 neuronal cells (generously provided by Dr C Cepko; Harvard Medical School) were maintained in Dulbecco's modi®ed medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (Ryder et al., 1990) . Prior to co-culture with primary astrocytes, C17 cells were lightly ®xed in 0.1% paraformaldehyde and washed extensively in media (10 000 cells each per well; 6 wells/condition). In these experiments, 10 000 ®xed C17 cells were co-cultured with 10 000 primary astrocytes for 72 h prior to the addition of 1 mCi/well of tritiated thymidine for an additional 24 h. Ten thousand primary astrocytes were cultured in parallel wells in the absence of C17 cells. No thymidine incorporation was observed in the ®xed C17 cells when cultured independently in separate wells (data not shown). In the MEK inhibition experiment, PD98059 was added to a ®nal concentration of 50 mM in each well for the 24 h in which the tritiated thymidine was included. For each experiment, the mean and standard deviation of the six wells per condition were determined.
Cell counting
Forty micron sections generated on a microtome were prepared for¯oating section immunohistochemistry using GFAP (Zymed), APC (Calbiochem) and mac-1 (Chemicon) antibodies as previously described (Norton et al., 1995a,b; Geist et al., 1996) . Development was accomplished using biotinylated secondary antibodies and ABC Elite (Vector) reagents with DAB or Vector-SG. Landmarks for astrocyte counting were established using a standard mouse brain atlas (Paxinos and Watson, 1986) . Only cells containing clearly de®ned nuclei within the focal plane of the section were counted in at least six consecutive serial sections from at least six mice matched for sex or genotype. BrdU incorporation was performed by a single intraperitoneal injection of 5 mg BrdU (Sigma) per g body weight of mice at least 2 months of age (20 ± 30 gms) 2 days prior to euthanasia and analysed by double labeling immunohistochemistry with BrdU (Sigma) and GFAP antibodies. BrdU was detected using mouse biotinylated secondary antibodies and Vector-SG development (blue reaction product) while GFAP was detected using rat biotinylated secondary antibodies and DAB development (brown reaction product). The percentage of GFAPimmunoreactive cells with BrdU-immunoreactive nuclei was scored.
